Previous 10 | Next 10 |
2023-06-02 15:00:55 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-05-18 08:20:30 ET FibroGen's ( NASDAQ: FGEN ) oral drug roxadustat was good as recombinant erythropoietin alfa (SEPO) in improving hemoglobin (Hb) level in a phase 3 trial to treat anemia in patients receiving chemotherapy for non-myeloid malignancies in China. Anemia ...
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology D...
2023-05-08 23:14:06 ET FibroGen, Inc. (FGEN) Q1 2023 Earnings Conference Call May 08, 2023 05:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief F...
2023-05-08 16:41:25 ET FibroGen press release ( NASDAQ: FGEN ): Q1 GAAP EPS of -$0.81 misses by $0.02 . Revenue of $36.16M (-40.6% Y/Y) beats by $4.64M . At March 31, 2023, cash – defined as cash, cash equivalents, investments, and accounts receivable ...
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics ...
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancers Collaboration expands FibroGen’s clinical pipeline with potential first-in-class product candidate SAN FRANCISCO and LA JOLLA, Calif., May 08, 2023...
SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy en...
2023-05-01 07:43:15 ET FibroGen ( NASDAQ: FGEN ) announces a term loan facility with investment funds managed by Morgan Stanley Tactical Value or MSTV of up to $150M. The $150M term loan facility will be available to the company in three tranches: the initial tranche of ...
Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical pipeline FibroGen will receive up to $150 million in total cash ...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...